Eugene T Richardson, M.D., Ph.D.
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Hemorrhagic Fever, Ebola | 15 | 2024 | 420 | 4.640 |
Why?
|
Ebolavirus | 7 | 2023 | 252 | 2.040 |
Why?
|
Disease Outbreaks | 11 | 2024 | 1759 | 1.510 |
Why?
|
Science | 2 | 2020 | 240 | 0.890 |
Why?
|
Africa, Western | 5 | 2024 | 159 | 0.810 |
Why?
|
Civil Disorders | 1 | 2020 | 8 | 0.750 |
Why?
|
Seroepidemiologic Studies | 2 | 2021 | 393 | 0.720 |
Why?
|
Epidemics | 3 | 2024 | 513 | 0.720 |
Why?
|
Public Assistance | 1 | 2017 | 47 | 0.590 |
Why?
|
Tuberculosis | 3 | 2016 | 2003 | 0.590 |
Why?
|
Virus Diseases | 1 | 2023 | 721 | 0.580 |
Why?
|
Air Pollution | 2 | 2023 | 2316 | 0.550 |
Why?
|
Sierra Leone | 5 | 2021 | 168 | 0.540 |
Why?
|
Carbon Dioxide | 2 | 2016 | 1145 | 0.480 |
Why?
|
Mining | 1 | 2014 | 91 | 0.450 |
Why?
|
Ventilation | 1 | 2014 | 128 | 0.440 |
Why?
|
Loiasis | 1 | 2012 | 2 | 0.420 |
Why?
|
Vaccines | 1 | 2021 | 833 | 0.410 |
Why?
|
Isoniazid | 1 | 2014 | 283 | 0.410 |
Why?
|
Chemoprevention | 1 | 2014 | 326 | 0.400 |
Why?
|
Eyelid Diseases | 1 | 2012 | 157 | 0.350 |
Why?
|
Cluster Analysis | 1 | 2016 | 2698 | 0.320 |
Why?
|
Pandemics | 2 | 2020 | 8621 | 0.300 |
Why?
|
Delayed Diagnosis | 1 | 2012 | 463 | 0.300 |
Why?
|
Edema | 1 | 2012 | 772 | 0.300 |
Why?
|
Biomedical Research | 2 | 2014 | 3421 | 0.280 |
Why?
|
Survivors | 1 | 2017 | 2367 | 0.280 |
Why?
|
Public Health | 1 | 2020 | 2655 | 0.280 |
Why?
|
Prevalence | 4 | 2024 | 15687 | 0.270 |
Why?
|
Research Personnel | 1 | 2011 | 584 | 0.270 |
Why?
|
Democratic Republic of the Congo | 3 | 2020 | 86 | 0.270 |
Why?
|
Antiretroviral Therapy, Highly Active | 2 | 2016 | 1894 | 0.270 |
Why?
|
Travel | 1 | 2012 | 786 | 0.260 |
Why?
|
HIV Infections | 5 | 2016 | 17159 | 0.260 |
Why?
|
Socioeconomic Factors | 2 | 2017 | 7803 | 0.260 |
Why?
|
Antitubercular Agents | 1 | 2014 | 1374 | 0.250 |
Why?
|
Antibodies, Viral | 1 | 2016 | 3145 | 0.250 |
Why?
|
Models, Psychological | 2 | 2017 | 826 | 0.240 |
Why?
|
Anti-Retroviral Agents | 1 | 2013 | 1780 | 0.230 |
Why?
|
Anthropology, Cultural | 1 | 2024 | 101 | 0.220 |
Why?
|
Tears | 1 | 2024 | 251 | 0.200 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3086 | 0.200 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3206 | 0.200 |
Why?
|
Louisiana | 1 | 2021 | 104 | 0.190 |
Why?
|
Thailand | 2 | 2019 | 289 | 0.190 |
Why?
|
Philosophy, Medical | 1 | 2001 | 79 | 0.180 |
Why?
|
Institutionalization | 1 | 2001 | 105 | 0.180 |
Why?
|
Humans | 33 | 2024 | 760261 | 0.170 |
Why?
|
Hospitals, Psychiatric | 1 | 2001 | 321 | 0.170 |
Why?
|
Antiphospholipid Syndrome | 1 | 2020 | 165 | 0.160 |
Why?
|
Republic of Korea | 1 | 2021 | 567 | 0.160 |
Why?
|
Clinical Trials as Topic | 1 | 2014 | 8058 | 0.150 |
Why?
|
Space Perception | 1 | 2001 | 464 | 0.150 |
Why?
|
Climate Change | 1 | 2023 | 488 | 0.140 |
Why?
|
Water | 1 | 2023 | 1402 | 0.140 |
Why?
|
Semantics | 1 | 2001 | 599 | 0.140 |
Why?
|
International Educational Exchange | 1 | 2016 | 49 | 0.140 |
Why?
|
Social Justice | 1 | 2021 | 478 | 0.140 |
Why?
|
Human Rights | 2 | 2016 | 306 | 0.140 |
Why?
|
Practice Guidelines as Topic | 1 | 2013 | 7468 | 0.130 |
Why?
|
Quality of Life | 1 | 2017 | 13300 | 0.130 |
Why?
|
RNA, Viral | 1 | 2024 | 2837 | 0.130 |
Why?
|
Panuveitis | 1 | 2015 | 33 | 0.130 |
Why?
|
Immunocompromised Host | 1 | 2020 | 857 | 0.120 |
Why?
|
Aqueous Humor | 1 | 2015 | 154 | 0.120 |
Why?
|
Crowding | 1 | 2016 | 142 | 0.120 |
Why?
|
Poverty Areas | 1 | 2016 | 264 | 0.120 |
Why?
|
Transportation | 1 | 2016 | 214 | 0.120 |
Why?
|
Bisexuality | 1 | 2016 | 271 | 0.120 |
Why?
|
Nigeria | 2 | 2016 | 762 | 0.110 |
Why?
|
Violence | 1 | 2019 | 927 | 0.110 |
Why?
|
Diethylcarbamazine | 1 | 2012 | 23 | 0.100 |
Why?
|
Filaricides | 1 | 2012 | 10 | 0.100 |
Why?
|
Food Supply | 1 | 2018 | 542 | 0.100 |
Why?
|
Attitude to Health | 1 | 2001 | 2028 | 0.100 |
Why?
|
Cross-Sectional Studies | 4 | 2024 | 25928 | 0.100 |
Why?
|
Health Facilities | 1 | 2016 | 578 | 0.100 |
Why?
|
Developed Countries | 1 | 2013 | 443 | 0.090 |
Why?
|
South Africa | 1 | 2016 | 1821 | 0.090 |
Why?
|
Clinical Clerkship | 1 | 2016 | 563 | 0.090 |
Why?
|
Enzyme-Linked Immunosorbent Assay | 1 | 2016 | 3804 | 0.080 |
Why?
|
Viral Proteins | 1 | 2016 | 1802 | 0.080 |
Why?
|
Peer Review | 1 | 2011 | 218 | 0.080 |
Why?
|
Program Evaluation | 1 | 2017 | 2494 | 0.080 |
Why?
|
Homosexuality, Male | 1 | 2016 | 1269 | 0.080 |
Why?
|
Vision Disorders | 1 | 2015 | 1084 | 0.080 |
Why?
|
Young Adult | 4 | 2018 | 58673 | 0.070 |
Why?
|
Environmental Monitoring | 1 | 2014 | 1441 | 0.070 |
Why?
|
World Health Organization | 1 | 2013 | 1319 | 0.070 |
Why?
|
Qualitative Research | 1 | 2017 | 2958 | 0.070 |
Why?
|
Male | 12 | 2024 | 359413 | 0.070 |
Why?
|
Models, Theoretical | 1 | 2019 | 3561 | 0.070 |
Why?
|
Air Pollution, Indoor | 1 | 2014 | 891 | 0.070 |
Why?
|
Vaccination | 1 | 2019 | 3360 | 0.070 |
Why?
|
Adolescent | 4 | 2018 | 87747 | 0.070 |
Why?
|
Schools | 1 | 2014 | 1474 | 0.060 |
Why?
|
Developing Countries | 2 | 2016 | 2880 | 0.060 |
Why?
|
Eye Infections, Viral | 1 | 2024 | 60 | 0.060 |
Why?
|
Students, Medical | 1 | 2016 | 1926 | 0.050 |
Why?
|
Attitude of Health Personnel | 1 | 2016 | 3870 | 0.050 |
Why?
|
Health Status Disparities | 1 | 2014 | 1819 | 0.050 |
Why?
|
Child | 2 | 2023 | 79758 | 0.050 |
Why?
|
Asymptomatic Infections | 1 | 2023 | 131 | 0.050 |
Why?
|
Adult | 5 | 2024 | 219847 | 0.050 |
Why?
|
Nursing Methodology Research | 1 | 2001 | 64 | 0.050 |
Why?
|
United States | 3 | 2021 | 72363 | 0.050 |
Why?
|
Logic | 1 | 2001 | 42 | 0.050 |
Why?
|
Quality of Health Care | 1 | 2016 | 4361 | 0.050 |
Why?
|
Mental Disorders | 1 | 2001 | 6797 | 0.050 |
Why?
|
Anti-HIV Agents | 1 | 2016 | 4492 | 0.040 |
Why?
|
Sex Factors | 1 | 2014 | 10530 | 0.040 |
Why?
|
Female | 7 | 2024 | 391011 | 0.040 |
Why?
|
Periodicals as Topic | 1 | 2011 | 1470 | 0.040 |
Why?
|
Incidence | 2 | 2016 | 21378 | 0.040 |
Why?
|
Knowledge | 1 | 2001 | 176 | 0.040 |
Why?
|
Family Characteristics | 1 | 2024 | 1001 | 0.040 |
Why?
|
Middle Aged | 5 | 2024 | 220175 | 0.040 |
Why?
|
Time | 1 | 2019 | 545 | 0.040 |
Why?
|
Bolivia | 1 | 2016 | 22 | 0.040 |
Why?
|
Gambia | 1 | 2016 | 104 | 0.030 |
Why?
|
Prejudice | 1 | 2001 | 563 | 0.030 |
Why?
|
Legislation as Topic | 1 | 2016 | 77 | 0.030 |
Why?
|
Fatal Outcome | 1 | 2020 | 1833 | 0.030 |
Why?
|
Russia | 1 | 2016 | 381 | 0.030 |
Why?
|
Organizations | 1 | 2016 | 171 | 0.030 |
Why?
|
Kenya | 1 | 2016 | 749 | 0.030 |
Why?
|
Reproducibility of Results | 1 | 2011 | 20048 | 0.030 |
Why?
|
Job Satisfaction | 1 | 2016 | 539 | 0.030 |
Why?
|
Animals | 1 | 2023 | 167940 | 0.020 |
Why?
|
Viral Load | 1 | 2020 | 3323 | 0.020 |
Why?
|
China | 1 | 2016 | 2340 | 0.020 |
Why?
|
International Cooperation | 1 | 2016 | 1436 | 0.020 |
Why?
|
India | 1 | 2016 | 2346 | 0.020 |
Why?
|
Interviews as Topic | 1 | 2016 | 2656 | 0.020 |
Why?
|
Minority Groups | 1 | 2016 | 1199 | 0.020 |
Why?
|
Aged | 2 | 2024 | 168995 | 0.020 |
Why?
|
Longitudinal Studies | 1 | 2024 | 14482 | 0.020 |
Why?
|
Leadership | 1 | 2016 | 1372 | 0.020 |
Why?
|
Prospective Studies | 2 | 2024 | 54263 | 0.020 |
Why?
|
Sexual Behavior | 1 | 2016 | 2080 | 0.020 |
Why?
|
Emergency Medical Services | 1 | 2016 | 1927 | 0.020 |
Why?
|
Education, Medical | 1 | 2016 | 1728 | 0.010 |
Why?
|
Health Personnel | 1 | 2016 | 3310 | 0.010 |
Why?
|
Risk Assessment | 1 | 2023 | 24086 | 0.010 |
Why?
|
Cohort Studies | 1 | 2023 | 41317 | 0.010 |
Why?
|
Delivery of Health Care | 1 | 2016 | 5324 | 0.010 |
Why?
|
Risk Factors | 1 | 2018 | 74269 | 0.010 |
Why?
|